Literature DB >> 11202239

Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment.

F Puppo1, F Torre, P Contini, M Ghio, S Brenci, R Brizzolara, N Sinelli, N Campo, F Indiveri, A Picciotto.   

Abstract

The serum levels of soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chains were determined in 28 interferon-alpha nonresponder chronic hepatitis C patients retreated with interferon-alpha plus ribavirin and in 70 healthy subjects. The baseline levels of beta2-mu-associated and beta2-mu-free HLA class I heavy chains were significantly higher in patients than in healthy controls (P = 0.001). The levels of beta2-mu-associated HLA class I heavy chains significantly increased in responder patients with respect to nonresponders at the third month of treatment (P = 0.03). At the sixth month of treatment and after 6 months of follow up the levels of beta2-mu-associated HLA class I heavy chains decreased in responder patients and increased in nonresponders. The levels of beta2-mu-free HLA class I heavy chains showed only minor changes during and after treatment. We suggest that the determination of hepatitis C virus RNA levels combined with soluble beta2-mu-associated HLA class I heavy chains, as a marker of immune activation, could identify interferon-alpha non responder chronic hepatitis C patients most likely to respond to a retreatment with interferon-alpha plus ribavirin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11202239     DOI: 10.1023/a:1026468001834

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  35 in total

1.  The origin and fate of beta 2m-free MHC class I molecules induced on activated T cells.

Authors:  S Demaria; R Schwab; Y Bushkin
Journal:  Cell Immunol       Date:  1992-06       Impact factor: 4.868

2.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.

Authors:  N J Stam; H Spits; H L Ploegh
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

Review 3.  Therapy of hepatitis C.

Authors:  M W Fried; J H Hoofnagle
Journal:  Semin Liver Dis       Date:  1995-02       Impact factor: 6.115

4.  The soluble pool of beta 2-microglobulin free HLA class I alpha-chains. Qualitative and quantitative characterization.

Authors:  W F Pickl; O Majdic; I Faé; R Reuschel; W Holter; W Knapp
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

5.  Two forms of HLA class I molecules in human plasma.

Authors:  M S Krangel
Journal:  Hum Immunol       Date:  1987-10       Impact factor: 2.850

6.  Biochemical complexity of serum HLA class I molecules.

Authors:  L M Dobbe; N J Stam; J J Neefjes; M J Giphart
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

7.  Soluble beta 2-microglobulin-free class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease.

Authors:  S Demaria; R Schwab; S R Gottesman; Y Bushkin
Journal:  J Biol Chem       Date:  1994-03-04       Impact factor: 5.157

8.  Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients.

Authors:  P Giacomini; R Fraioli; A M Calabrò; F Di Filippo; P G Natali
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

9.  A double determinant immunoassay for HLA class I typing using serum as an antigen source.

Authors:  C Russo; M Fotino; A Carbonara; S Ferrone
Journal:  Hum Immunol       Date:  1987-05       Impact factor: 2.850

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

View more
  3 in total

1.  Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.

Authors:  Giuseppe Murdaca; Paola Contini; Paola Cagnati; Simona Marenco; Giulia Pieri; Francesca Lantieri; Antonino Picciotto; Francesco Puppo
Journal:  Clin Exp Med       Date:  2015-11-14       Impact factor: 3.984

2.  Influence of hepatitis C virus coinfection on failure of HIV-infected patients receiving highly active antiretroviral therapy to achieve normal serum beta2microglobulin levels.

Authors:  J A García-García; J A Mira; J Fernández-Rivera; A J Ramos; J Vargas; J Macías; J A Pineda
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-01       Impact factor: 3.267

3.  Quantitative Proteomic Analysis Reveals That Arctigenin Alleviates Concanavalin A-Induced Hepatitis Through Suppressing Immune System and Regulating Autophagy.

Authors:  Qin Feng; Jingchun Yao; Ge Zhou; Wenkai Xia; Jingang Lyu; Xin Li; Tao Zhao; Guimin Zhang; Ningwei Zhao; Jie Yang
Journal:  Front Immunol       Date:  2018-08-16       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.